HK Stock Market Move | SIHUAN PHARM(00460) rises more than 4% and signs a cooperation agreement with American company AbaloneBio to deepen its layout in the GPCR target field.

SIHUAN PHARM (00460) rose more than 4%, as of press time, up 3.42% to HKD 1.51, with a turnover of HKD 46.35 million. On the news front, on October 30, SIHUAN PHARM announced that the group has officially signed a cooperation agreement with the US biotechnology company AbaloneBio (Abalone). According to the agreement, the two parties will collaborate globally to advance the research and development of a new generation of innovative drugs for obesity treatment. The core goal of this research and development project is to achieve safe and effective energy expenditure enhancement by targeting and activating metabolism-related G protein-coupled receptors (GPCRs), while also maintaining or enhancing muscle mass, aiming to address the limitations of current weight loss therapies and meet the clinical needs in the global obesity treatment field that have not been adequately covered, and to promote the optimization and upgrading of treatment options in this field. The announcement stated that the cooperation between the group and Abalone is based on the previous foundation - the group completed a strategic investment in Abalone earlier this year. The signing of this cooperation agreement marks the extension of the cooperation between the two parties from the capital level to the business execution level, further consolidating the group's innovative layout in the field of weight loss, and leveraging Abalone's technological advantages to accelerate the research and development progress of the new generation of weight loss and muscle-building therapy, providing support for the group's long-term strategic development. In addition, this cooperation is also an important step for the group to deepen its layout in the field of GPCR targets.